BiotechTubeBiotechTube
Home/Pipeline/UCB0022

UCB0022

Alzheimer's Disease

Phase 1Active

Key Facts

Indication
Alzheimer's Disease
Phase
Phase 1
Status
Active
Company
UCB

About UCB

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

View full company profile

Therapeutic Areas

NeurologyImmunologyEpilepsyParkinson's DiseaseMultiple SclerosisRheumatoid ArthritisPsoriasisInflammatory Diseases

Other Alzheimer's Disease Drugs

DrugCompanyPhase
DonanemabEli LillyPhase 3
ALN-APPAlnylam PharmaceuticalsPhase 1
Alzheimer's Disease ProgramRocheVarious
Lecanemab (Leqembi)EisaiCommercial
ARO-MAPTArrowhead PharmaceuticalsPre-clinical
AMBAR®GrifolsClinical
Lu AG08854 (L1CAM mAb)LundbeckPreclinical
DNL919Denali TherapeuticsPhase 1b
BAN2802BioArctic ABPreclinical
Lecanemab SCBioArctic ABPhase 3
Undisclosed ProgramuniQurePreclinical
NVG-291NervGen PharmaPhase 1b/2a